	US 11,913,023 B2
	Modified B cells and methods of use thereof
Kathleen Boyle, Alameda, CA (US); Hangil Park, San Francisco, CA (US); Srinivas Kothakota, Pacifica, CA (US); Mark Selby, San Francisco, CA (US); Thomas Brennan, Cupertino, CA (US); and Lewis T. Williams, Mill Valley, CA (US)
Assigned to Walking Fish Therapeutics, Inc., South San Francisco, CA (US)
Filed by Walking Fish Therapeutics, South San Francisco, CA (US)
Filed on Sep. 2, 2021, as Appl. No. 17/465,759.
Application 17/465,759 is a continuation of application No. PCT/US2021/025273, filed on Mar. 31, 2021.
Claims priority of provisional application 63/073,799, filed on Sep. 2, 2020.
Claims priority of provisional application 63/003,120, filed on Mar. 31, 2020.
Prior Publication US 2022/0073876 A1, Mar. 10, 2022
Int. Cl. C12N 5/0781 (2010.01); A61K 35/17 (2015.01); C07K 16/30 (2006.01)

CPC C12N 5/0635 (2013.01) [A61K 35/17 (2013.01); C07K 16/303 (2013.01); C07K 16/3069 (2013.01); C07K 2317/53 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C12N 2510/00 (2013.01)]

32 Claims

1. A modified B cell comprising a chimeric receptor,

wherein said chimeric receptor comprises

a) an extracellular domain comprising an extracellular binding domain;

b) a transmembrane domain; and

c) a cytoplasmic domain comprising a signaling domain, said signaling domain comprising CD79a,

wherein, upon binding of the extracellular binding domain to a target antigen or protein, the modified B cell is activated and presents an antigen or an antigen-derived epitope in an HLA or MHC complex.